CO4940427A1 - Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina - Google Patents

Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Info

Publication number
CO4940427A1
CO4940427A1 CO98014184A CO98014184A CO4940427A1 CO 4940427 A1 CO4940427 A1 CO 4940427A1 CO 98014184 A CO98014184 A CO 98014184A CO 98014184 A CO98014184 A CO 98014184A CO 4940427 A1 CO4940427 A1 CO 4940427A1
Authority
CO
Colombia
Prior art keywords
composition
prostaglandine
increasing
present
agent
Prior art date
Application number
CO98014184A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Warren Reed
Yen Shau-Fong
Mary Sou
Flinn Peacock Regina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4940427A1 publication Critical patent/CO4940427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO98014184A 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina CO4940427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CO4940427A1 true CO4940427A1 (es) 2000-07-24

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98014184A CO4940427A1 (es) 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Country Status (32)

Country Link
EP (1) EP0969846B2 (https=)
JP (2) JP4920124B2 (https=)
KR (1) KR100555818B1 (https=)
CN (1) CN1236775C (https=)
AR (2) AR002194A1 (https=)
AT (1) ATE257385T1 (https=)
AU (1) AU738781B2 (https=)
BR (2) BR9808016A (https=)
CA (1) CA2280089C (https=)
CL (1) CL2009001870A1 (https=)
CO (1) CO4940427A1 (https=)
CY (1) CY2526B1 (https=)
CZ (1) CZ299833B6 (https=)
DE (1) DE69820997T3 (https=)
DK (1) DK0969846T4 (https=)
EE (1) EE04091B1 (https=)
ES (1) ES2214706T5 (https=)
HU (1) HU228896B1 (https=)
ID (1) ID22389A (https=)
IL (1) IL131041A0 (https=)
MY (1) MY122237A (https=)
NO (1) NO327713B1 (https=)
NZ (1) NZ337322A (https=)
PE (1) PE61899A1 (https=)
PL (1) PL197509B1 (https=)
PT (1) PT969846E (https=)
RU (1) RU2197970C2 (https=)
SI (1) SI0969846T2 (https=)
TW (1) TW527187B (https=)
UA (1) UA63938C2 (https=)
WO (1) WO1998041208A1 (https=)
ZA (1) ZA982188B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
WO2005089755A1 (en) * 2004-03-18 2005-09-29 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
WO2007015510A1 (ja) * 2005-08-02 2007-02-08 Santen Pharmaceutical Co., Ltd. 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
AU2007227091B2 (en) * 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
WO2008055205A2 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
PT2254549E (pt) * 2008-03-17 2014-01-30 Alcon Res Ltd Composições farmacêuticas aquosas que contêm complexos de borato-poliol
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
ES2797650T3 (es) 2011-12-07 2020-12-03 Allergan Inc Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
WO2020210784A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059058T3 (es) * 1990-05-22 1994-11-01 R Tech Ueno Ltd Combinacion sinergica para uso oftalmico.
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
CN1129400A (zh) * 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
EP0969846B2 (en) 2010-08-25
TW527187B (en) 2003-04-11
CZ299833B6 (cs) 2008-12-10
AU738781B2 (en) 2001-09-27
CZ325799A3 (cs) 2000-01-12
PL197509B1 (pl) 2008-04-30
AU7035398A (en) 1998-10-12
ATE257385T1 (de) 2004-01-15
EE04091B1 (et) 2003-08-15
HUP0002194A3 (en) 2012-08-28
RU2197970C2 (ru) 2003-02-10
KR100555818B1 (ko) 2006-03-03
HUP0002194A2 (hu) 2000-12-28
EP0969846B1 (en) 2004-01-07
WO1998041208A1 (en) 1998-09-24
CA2280089C (en) 2009-03-03
KR20000076330A (ko) 2000-12-26
ZA982188B (en) 1998-09-17
MY122237A (en) 2006-04-29
CL2009001870A1 (es) 2010-01-22
HU228896B1 (en) 2013-06-28
ID22389A (id) 1999-10-07
JP4920124B2 (ja) 2012-04-18
AR002194A1 (es) 1998-01-07
DE69820997D1 (de) 2004-02-12
ES2214706T3 (es) 2004-09-16
AR011192A1 (es) 2000-08-02
JP2001515502A (ja) 2001-09-18
BR9808016A (pt) 2000-03-08
IL131041A0 (en) 2001-01-28
UA63938C2 (uk) 2004-02-16
EP0969846A1 (en) 2000-01-12
DK0969846T3 (da) 2004-04-13
NO994481D0 (no) 1999-09-16
HK1026841A1 (en) 2000-12-29
CN1236775C (zh) 2006-01-18
NO994481L (no) 1999-09-16
CY2526B1 (en) 2006-02-08
SI0969846T1 (en) 2004-06-30
PT969846E (pt) 2004-05-31
BRPI9816218B1 (pt) 2016-04-12
DE69820997T2 (de) 2004-12-09
PL335168A1 (en) 2000-04-10
CA2280089A1 (en) 1998-09-24
EE9900410A (et) 2000-04-17
ES2214706T5 (es) 2011-02-02
JP2010043110A (ja) 2010-02-25
NZ337322A (en) 2001-05-25
NO327713B1 (no) 2009-09-14
CN1249687A (zh) 2000-04-05
DE69820997T3 (de) 2011-10-06
SI0969846T2 (sl) 2010-12-31
PE61899A1 (es) 1999-06-30
DK0969846T4 (da) 2010-12-20

Similar Documents

Publication Publication Date Title
CO4940427A1 (es) Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina
MX9803604A (es) Composiciones topicas para regular la apariencia grasosa/brillosa de la piel.
ES2160631T3 (es) Composiciones de retinoides para aplicacion topica.
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
DK1187601T3 (da) Hidtil ukendt præparat og administrationsform som omfatter en syrelabil protonpumpeinhibitor
YU23599A (sh) Stabilizovani antihistaminski sirup
CO4750715A1 (es) Metodos para la limpieza e higiene de productos agricolas, composiciones y articulos de comercio
CO4700416A1 (es) Composiciones de pantalla solar y metodo para preparar las mismas
ES2161886T3 (es) Composiciones en barra de gel que comprenden gelificantes opticamente enriquecidos.
CO5050388A1 (es) Formulaciones de bromo oxidantes, estables, metodos de fabricacion de las mismas y metodos de uso para el control del microensuciamiento
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
ATE174619T1 (de) Wäschenachbehandlungsmittel
ES2152517T3 (es) Composicion desodorante.
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
DK1339412T3 (da) Formulering, som indeholder phosphatderivater af elektronoverførselsmidler
DE50106211D1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
MA21093A1 (fr) Procede de regeneration du tournesol par embryogenese .
ATE270869T1 (de) ZUSAMMENSETZUNG MIT KONTINUIERLICHER WÄSSERIGER PHASE, DIE L-2-OXOTHIAZOLIDIN- 4-CARBONSÄURE ENTHÄLTß.
BR9908217A (pt) Composição desodorante, e, processo para inibição de odor corporal
ES2137158T3 (es) N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2058817T3 (es) Derivados de tetrahidronaftaleno y su preparacion.
JPS53144520A (en) Stabilization of unsaturated tert-amines or their quaternary ammonium salts
NO986041L (no) FremgangsmÕte ved behandling av plantesykdom
NO20006197L (no) Anvendelse av minst én syre av sitronsyrecyklusen i kombinasjon med glycerol som et insektsbekjempende middel
PE19798A1 (es) Compuestos fungicidas (b)